5 completed, 1 not yet recruiting, 1 recruiting. 5 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow durlobactam: new trials by email Literature Review of durlobactam trials Research Report on durlobactam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection | Phase 2 | Not yet recruiting | The University of Queensland | 300 | 2027-04-01 | 2026-03-20 |
| A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours) - Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC) | Phase 1 | Recruiting | Innoviva Specialty Therapeutics | 48 | 2026-12-30 | 2026-10-06 |
| Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex Sulbactam, Durlobactam, Colistin - Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia | Phase 3 | Completed | Entasis Therapeutics | 207 | 2019-09-05 | 2023-02-01 |
| Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects ETX2514, 14C-ETX2514 - Acinetobacter Baumannii-calcoaceticus Complex Infections | Phase 1 | Completed | Entasis Therapeutics | 8 | 2019-06-21 | 2019-08-30 |
| Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers ETX2514, Placebo, moxifloxacin - Acinetobacter Baumannii-calcoaceticus Complex Infections | Phase 1 | Completed | Entasis Therapeutics | 32 | 2019-05-23 | 2019-08-30 |
| Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects ETX2514 and sulbactam - Healthy | Phase 1 | Completed | Entasis Therapeutics | 30 | 2017-08-21 | 2017-11-09 |
| Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects ETX2514, Placebo, Sulbactam - Acinetobacter Baumannii Infection | Phase 1 | Completed | Entasis Therapeutics | 124 | 2016-10-01 | 2017-06-05 |
Infections (2) · Bacteremia (1) · Mycobacterium Infections, Nontuberculous (1)
Entasis Therapeutics (5) · Innoviva Specialty Therapeutics (1) · The University of Queensland (1)
United States (5) · Australia (1) · Belarus (1) · Brazil (1) · China (1) · Greece (1) · Hungary (1) · India (1) · Israel (1) · Lithuania (1) · Mexico (1) · Peru (1) · Puerto Rico (1) · Russia (1) · South Korea (1)
Jason Lickliter (1)